BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate

BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing a next-generation therapeutic. BioDlink provided end-to-end...